entertainment -WSS

entertainment

author：explore 2025-09-06 10:26:02 - browse：684

NICOLAS MAETERLINCK/BELGA MAG/AFP via Getty Images

LONDON — Novavax, the beleaguered maker of a Covid-19 vaccine, just got a boost of its own.

The French pharma company Sanofi on Friday said it had reached a licensing deal to sell Novavax’s Covid shot going forward as well as to try to combine the vaccine with Sanofi’s own flu shot. The pact includes a $500 million upfront payment, with up to $700 million more on the table if certain regulatory and launch milestones are reached.

While Novavax’s stock soared during the pandemic as the vaccine race was underway, the company failed to get its shot authorized in the U.S. market until July 2022, long after the makers of mRNA vaccines had reaped billions in sales. Sales have sputtered along since then, and last year, the Maryland-based company warned that that it may not be able to stay in business.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medicare details structure of new drug price negotiation program
Next article： Boston's new lab space is opening empty

focus

hotspot

WSS

Amylyx ALS drug fails trial: Relyvrio patients react with fear, worry

Amylyx ALS drug fails trial: Relyvrio patients react with fear, worry

Change Healthcare outage fallout shows need for new oversight

Obesity drug from Roche shows promise in early study

First U.S. drug developed to treat liver disease MASH is approved

Readout Newsletter: CAR

focus

entertainment

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

explore

Medicare details structure of new drug price negotiation program

President Biden's budget: Here's what you might have missed

How one medical school became remarkably diverse

Amid AI frenzy, a top HHS official's quest to create safeguards

Wildfire smoke exposes gaps in outdoor worker protections

WuXi out of biotech trade group, U.S. and China relations to blame

State Dept. review finds Biden bears some blame for Afghanistan failures

RaDonda Vaught links Vanderbilt hospital issues to patient death

Bright Health sells Medicare Advantage business to Molina

Steward Health Care Massachusetts hospitals face fiscal disaster

entertainment

President Biden's budget: Here's what you might have missed

WuXi Biologics beefs up its lobbying operation

RaDonda Vaught links Vanderbilt hospital issues to patient death

Ripples from Flovent's discontinuation is killing children with asthma

Abbott's new stent may help patients with peripheral artery disease

Readout Newsletter: Raw milk, Wegovy tests, Eisai and Biogen

hotspot

focus

hotspot

explore